ROCKVILLE, Md., May 10, 2010 /PRNewswire via COMTEX/ -- Neuralstem, Inc. (NYSE Amex: CUR) CEO and President, Richard Garr, has been invited to present at the Fifth Annual World Stem Cells and Regenerative Medicine Congress, held May 11-13, in London, UK http://www.terrapinn.com/2010/stemcells/index.stm.
Neuralstem is currently in a Phase I clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its spinal cord stem cells.
related investing news
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO ) Mr. Garr's talk, at 2:30 on Wednesday, May 12, is entitled "Goals, Challenges and Solutions for Bringing Cell-Based ALS Therapy to the Clinic." It will address the goals and scientific potential of applying cell therapy to ALS, as well as the challenges and solutions in bringing this treatment to patients.
About Neuralstem, Inc.
Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous system diseases including: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. ALS is a progressive fatal neurodegenerative disease that affects nerve cells in the brain, leading to the degeneration and death of the motor neurons in the spinal cord that control muscle movement. Neuralstem is in a Phase I clinical trial to treat ALS. For more information, please go to www.neuralstem.com.
Cautionary Statement Regarding Forward Looking Information This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements.
Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2009.
SOURCE Neuralstem, Inc.
www.prnewswire.com Copyright (C) 2010 PR Newswire. All rights reserved -0- KEYWORD: Maryland
England INDUSTRY KEYWORD: HEA
MTC SUBJECT CODE: TDS